Novartis issues voluntary nationwide recall of Promacta ® 12.5 mg for oral suspension due to potential peanut contamination

May 11, 2019

Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.

Promacta tablets in 12.5 mg, 25 mg, 50 mg and 75 mg strengths are not impacted by this recall and are not manufactured in the same facility.

- From Novartis Press Release

Read More

 

 

back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo